ELI LILLY AND COMPANY |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 860.6 USD | -0.51% |
|
+3.31% | +47.55% |
| 06:12pm | Swiss Market Index Falls as US Rate Jitters Persist | MT |
| 05:51pm | Global markets live: GSK, Tesla, Intel, General Motors, Gamestop... |  |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
Pharmaceuticals
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
865
USD
Average target price
855.2
USD
Spread / Average Target
-1.14%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +47.55% | 779B | |
| +40.67% | 631B | |
| -6.65% | 354B | |
| +20.36% | 333B | |
| +8.27% | 301B | |
| +16.75% | 249B | |
| -1.19% | 216B | |
| +10.85% | 214B | |
| +4.25% | 163B | |
| -2.52% | 159B |
- Stock Market
- Equities
- LLY Stock
- News Eli Lilly and Company
- Eli Lilly Appoints CordenPharma to Manufacture Active Ingredient for Diabetes Drug
